MX2018012900A - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents

Uso de beta-agonistas del receptor de la hormona tiroidea.

Info

Publication number
MX2018012900A
MX2018012900A MX2018012900A MX2018012900A MX2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A
Authority
MX
Mexico
Prior art keywords
agonists
thyroid beta
thyroid
beta
treating
Prior art date
Application number
MX2018012900A
Other languages
English (en)
Inventor
Jiang Hongjian
Lian Brian
Hanley Rochelle
Dinerman Misha
Erion Mark
Boyer Serge
Original Assignee
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viking Therapeutics Inc filed Critical Viking Therapeutics Inc
Publication of MX2018012900A publication Critical patent/MX2018012900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos útiles para tratar la adrenoleucodistrofia enlazada a X.
MX2018012900A 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea. MX2018012900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (1)

Publication Number Publication Date
MX2018012900A true MX2018012900A (es) 2019-07-01

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012900A MX2018012900A (es) 2016-04-22 2017-04-24 Uso de beta-agonistas del receptor de la hormona tiroidea.

Country Status (9)

Country Link
US (2) US11351183B2 (es)
EP (1) EP3445373A4 (es)
JP (1) JP6931042B2 (es)
KR (1) KR102407059B1 (es)
AU (1) AU2017252126B2 (es)
BR (1) BR112018071586A2 (es)
CA (1) CA3021681A1 (es)
MX (1) MX2018012900A (es)
WO (1) WO2017185087A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071586A2 (pt) 2016-04-22 2019-02-12 Viking Therapeutics, Inc. uso de beta-agonistas da tireoide
MX2020009843A (es) * 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
BRPI0518616A (pt) 2004-12-08 2008-01-15 Sirion Therapeutics Inc métodos para tratar doenças relacionadas com retinol, degeneração ou distrofia macular e diabetes tipo i ou tipo ii
JP2008545711A (ja) * 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド 新規ホスフィン酸含有甲状腺ホルモン様剤
EP1898926A2 (en) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2007097289A1 (ja) 2006-02-20 2007-08-30 Takeda Pharmaceutical Company Limited 新規医薬
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EP2723756B1 (en) 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
AU2016219794A1 (en) 2015-02-20 2017-09-07 Oregon Health & Science University Derivatives of sobetirome
CN108602613B (zh) 2016-02-29 2020-06-16 菲利普莫里斯生产公司 铰接盖容器和坯料
BR112018071586A2 (pt) 2016-04-22 2019-02-12 Viking Therapeutics, Inc. uso de beta-agonistas da tireoide
CN113730421A (zh) 2016-04-22 2021-12-03 维京治疗股份有限公司 甲状腺β-激动剂的应用
BR112018073679A2 (pt) 2016-05-18 2019-02-26 Oregon Health & Science University composto, composição farmacêutica e método de tratamento de um distúrbio neurodegenerativo

Also Published As

Publication number Publication date
WO2017185087A1 (en) 2017-10-26
EP3445373A1 (en) 2019-02-27
US20190321379A1 (en) 2019-10-24
AU2017252126B2 (en) 2023-02-09
JP2019515033A (ja) 2019-06-06
CA3021681A1 (en) 2017-10-26
EP3445373A4 (en) 2019-12-18
KR20190039027A (ko) 2019-04-10
US20220257618A1 (en) 2022-08-18
KR102407059B1 (ko) 2022-06-10
AU2017252126A1 (en) 2018-11-08
BR112018071586A2 (pt) 2019-02-12
US11351183B2 (en) 2022-06-07
US11951114B2 (en) 2024-04-09
JP6931042B2 (ja) 2021-09-01

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
GB2556286A (en) Programmable voltage reference
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2017001981A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016009858A (es) Fusiones anti proteína convertasa subtilisina/kexina tipo 9 (anti-pcsk9)n péptido 1 similar a glucagón (glp-1) y métodos de uso.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2020012893A (es) Formulaciones de proteinas.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2018012904A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
MX2018012900A (es) Uso de beta-agonistas del receptor de la hormona tiroidea.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
EP3094347A4 (en) Methods for enhancing the delivery of active agents
MX2016009541A (es) Metodo para tratar vajilla.
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
NZ744340A (en) Anti-jagged1 antibodies and methods of use
IN2014CH00872A (es)
UA98223U (ru) Высокоэнергетические эко пеллеты